Nagoya Protocol: ‘a masterpiece of ambiguity’

Since the Nagoya Protocol was implemented in October 2014, lawyers, academics, and the life sciences industry broadly have been calling upon institutions such as the European Union for guidance on how to best abide by the new regulations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

MedTech

Sun Pharma import ban back in force after Squires intervention

3 September 2026 A decision at the USPTO has cleared the way for renewed enforcement in the drugmaker’s dispute over light-based dermatology tech.

Careers

White & Case life sciences co-leader moves firms

2 September 2026 The senior transactions specialist brings experience advising pharmaceutical, biotechnology and technology companies on strategic alliances, licensing, M&A and cross-border transactions.

More features

10x Genomics wins latest round in Parse patent dispute

Sun Pharma import ban back in force after Squires intervention

White & Case life sciences co-leader moves firms

‘Busiest’ US district patent judge swaps bench for private practice

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

Pinsents expands German patent practice with partner duo

Tempus AI bid to derail DNA patent case hits snag

Top law firms and individuals recognised in WIPR’s UK Patent Rankings 2026

Nagoya Protocol: ‘a masterpiece of ambiguity’

More on this story

Editor's picks

Editor's picks

More features